Indio (111in) Cloruro Curium Netherlands (Indium (111in) Chloride)

After intravenous injection, Indium-111 chloride binds to plasma proteins and can be taken up by specific cells such as labeled white blood cells. Its gamma emissions are captured by imaging equipment, allowing clinicians to visualize areas of infection, tumor activity, or bone marrow function.

The prescribed dose of Indium-111 chloride is determined by the treating physician based on the specific diagnostic procedure, patient weight, and clinical indication. Dosing details are individualized and should follow the prescribing information.

Indium-111 chloride involves radiation exposure, which can pose risks to a developing fetus and may be secreted in breast milk. It should be avoided during pregnancy and breastfeeding unless the diagnostic benefit outweighs the potential risk, and only under strict medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Indium-111 chloride offers a longer half‑life and gamma emission suitable for cellular labeling, making it valuable for infection and bone marrow imaging. Compared with shorter‑lived agents like Technetium‑99m, it provides extended imaging windows but involves higher radiation dose, requiring careful patient selection.

The product should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. It must be handled in a controlled environment by trained personnel, using appropriate radiation safety measures and aseptic technique during preparation and administration.

Indium-111 chloride is administered intravenously by a qualified healthcare professional. The injection is typically performed in a nuclear medicine department, followed by a waiting period to allow the radiotracer to localize before imaging with a gamma camera.

Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced tissue injury, hemolysis, renal toxicity, and bone marrow suppression. Patients should be monitored closely during and after administration for any adverse events.

Indium-111 chloride should be avoided in patients with known hypersensitivity to the radiopharmaceutical, pregnant or nursing women unless absolutely necessary, individuals with severe renal impairment, and those receiving concurrent high‑dose radiation or certain chelating agents that could interfere with tracer binding.